153 related articles for article (PubMed ID: 35106659)
21. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
22. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
[TBL] [Abstract][Full Text] [Related]
25. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
Unek IT; Akman T; Oztop I; Unal OU; Salman T; Yilmaz U
Gastric Cancer; 2013 Jul; 16(3):428-34. PubMed ID: 23086560
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Tomasello G; Liguigli W; Poli R; Lazzarelli S; Brighenti M; Negri F; Curti A; Martinotti M; Olivetti L; Rovatti M; Donati G; Passalacqua R
Gastric Cancer; 2014 Oct; 17(4):711-7. PubMed ID: 24282019
[TBL] [Abstract][Full Text] [Related]
28. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Anter AH; Abdel-Latif RM
Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Petrioli R; Francini E; Cherri S; Marrelli D; Rovello F; Fiaschi AI; Miano ST; Savelli V; Calomino N; Farsi M; Vernillo R; Francini G
Anticancer Drugs; 2020 Mar; 31(3):292-297. PubMed ID: 31850915
[TBL] [Abstract][Full Text] [Related]
30. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
Keskin S; Yıldız I; Sen F; Aydogan F; Kilic L; Ekenel M; Saglam S; Sakar B; Disci R; Aykan F
Clin Transl Oncol; 2013 May; 15(5):403-8. PubMed ID: 23054756
[TBL] [Abstract][Full Text] [Related]
31. Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.
Catalano V; Vincenzi B; Giordani P; Graziano F; Santini D; Baldelli AM; Alessandroni P; Schiavon G; Rossi D; Casadei V; D'Emidio S; Luzi Fedeli S; Tonini G; Fiorentini G
Gastric Cancer; 2012 Oct; 15(4):419-26. PubMed ID: 22237659
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial.
Ahmadzadeh A; Seyedian SS; Valizadeh A; Soleimani M; Nazari P; Hamidi H
Asian Pac J Cancer Prev; 2020 Mar; 21(3):727-732. PubMed ID: 32212800
[TBL] [Abstract][Full Text] [Related]
33. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Bozkaya Y; Doğan M; Yazıcı O; Erdem GU; Demirci NS; Zengin N
Bosn J Basic Med Sci; 2017 May; 17(2):138-143. PubMed ID: 28273032
[TBL] [Abstract][Full Text] [Related]
35. [Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Kang SH; Kim JI; Goh PG; Hwang SW; Kwon DS; Nam KW; Kang HM; Kang YS; Moon HS; Kim SH; Seong JK; Lee BS; Jeong HY
Korean J Gastroenterol; 2007 Sep; 50(3):157-63; discussion 207-9. PubMed ID: 17885280
[TBL] [Abstract][Full Text] [Related]
36. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
37. Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as a Neoadjuvant Chemotherapy for Non-metastatic Esophageal Cancer (nMEC).
Onitilo AA; Stankowski-Drengler TJ; Shiyanbola O; Engel J; Tanimu S; Fagbemi SO; Li YH
Clin Med Res; 2021 Jun; 19(2):64-71. PubMed ID: 33789952
[No Abstract] [Full Text] [Related]
38. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.
Chen XL; Chen XZ; Yang C; Liao YB; Li H; Wang L; Yang K; Li K; Hu JK; Zhang B; Chen ZX; Chen JP; Zhou ZG
PLoS One; 2013; 8(4):e60320. PubMed ID: 23593191
[TBL] [Abstract][Full Text] [Related]
40. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Lorenzen S; Hentrich M; Haberl C; Heinemann V; Schuster T; Seroneit T; Roethling N; Peschel C; Lordick F
Ann Oncol; 2007 Oct; 18(10):1673-9. PubMed ID: 17660494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
